Delivering forward, science-based thinking to help executives and investors mitigate risk and increase success in biopharma innovation.
Identify the companies, programs and investors in your defined market
Develop a nuanced understanding of your target sector with data and analysis
Understand trends and issues shaping the future of your target market
Create a refined target list of potential partners from full biopharma universe
Evaluate potential partners by exploring their pipelines, funding, deals and strategies
Prepare for meetings with both data and context
Identify translational science threats in relevant targets, diseases and technologies
Create alerts for product and strategic developments at competing companies
Monitor investments in your therapeutic and technology spaces
Use Company Profiles to identify comparable programs across the industry
Review investing and partnering deals in your pipeline or program space
Understand where your program fits in the industry pipeline
The authoritative resource to stay up to date with facts, explanation and interpretation.
New variant is first real test of biopharma’s adaptability against the virus
FDA, NIH leaders want to help the business case for ultra-rare disease gene therapies. FNIH’s Bespoke Gene Therapy Consortium is the vehicle
Complex information, simplified visually.
Five submissions under FDA priority review
China’s top fundraisers show ambitions beyond me-too, me-better
BioCentury's streaming commentary on industry trends, plus interviews with leading KOLs.
BioCentury This Week podcast also features the latest strategies for optimizing the potency of TCR-based cancer therapies
BioCentury’s latest podcast discusses how Biogen’s next head of R&D should think about the biotech’s therapeutic focus
Research and insights on market trends and best practices from BioCentury and our selected sponsors and collaborators.
BioCentury's spotlight on "Real-World Evidence" highlights BioCentury's recent coverage and analysis into the opportunities for Western pharmaceutical companies to accelerate drug development processes in China using the Real World Evidence (RWE) approval pathway.
BioCentury's popular "Korea Spotlight" series heads to the China Summit where a panel of Korea biotech CEOs discuss opportunities for cross-border partnerships and drug development.
To stage its Next Act, Europe will need to transform its powerhouse of scientific research into a pipeline of new medicines with global impact. How — and where — will Europe create more leading biotechs to make this happen? To answer that question, Insights Partner McKinsey & Co. returns with its new exclusive report for Bio€quity Europe. This second annual report builds on McKinsey’s leading analysis of Europe’s “Innovation Hot Spots,” addressing key questions about the trajectory of these evolving centers of excellence and how they measure up to key metrics for growth and success.
Sponsor Edition - Eight parameters to optimize your technology strategy
Disruptions to clinical trials that prevent or limit site access to patients, monitors, and CRAs are propelling long-lasting changes in the research industry, supported by the adoption of trial virtualization technologies. Download this eBook to learn eight parameters that are driving the successful response and approach to decentralized trials to guide sponsors in optimizing their technology strategy.
The exclusive Broadening the Bridge to Innovation by McKinsey & Company was commissioned for the 7th BioCentury-BayHelix China Healthcare Summit (Nov. 9-13, 2020, Digital Event).
BioCentury's insights on seminal issues affecting the biotech industry.
Stretching the vision of accelerated approval
This week, biotech saw one of its most momentous decisions since the industry’s foundation, with the FDA approval of Biogen’s aducanumab, an anti-amyloid mAb to treat Alzheimer’s
ODAC meeting poses challenges for FDA
The threat of vaccine nationalism and the forces working against it
BioCentury calls on industry to convert its COVID response to a new era of efficient drug development and address the urgent healthcare chasms exposed by the crisis